Vitrasert for cytomegalovirus (CMV) retinitis
April 1996
The FDA just approved Vitrasert for cytomegalovirus (CMV) retinitis. Vitrasert is implanted surgically in the eye. It releases the antiviral ganciclovir for about six months.
The implant works better than IV ganciclovir...probably because it achieves higher drug levels in the eye.
Vitrasert DOESN'T prevent CMV infections in the other eye or elsewhere in the body. Expect to see some patients get combo therapy with Vitrasert AND systemic ganciclovir (Cytovene).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote